14.22

3.52% 0.31

Mediwound Ltd (MDWD)

Overview News Price History Option Chain Discussions Forecast Stock Split

Mediwound Ltd stock is traded at $14.22, with a volume of 6,622. It is up +3.52% in the last 24 hours and up +1.05% over the past month. MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Previous Close:

$13.91

Open:

$14.06

24h Volume:

6,622

Relative Volume:

0.08

Market Cap:

$182.76M

Revenue:

$14.48M

Net Income/Loss:

$-26.11M

P/E Ratio:

-6.2945

EPS:

-2.2591

Net Cash Flow:

$-23.86M

1W Performance:

+0.84%

1M Performance:

+1.05%

6M Performance:

-16.62%

1Y Performance:

-23.20%

1-Day Range:

$14.06

$14.41

1-Week Range:

$13.80

$14.55

52-Week Range:

$13.54

$20.30

Mediwound Ltd Stock (MDWD) Company Profile

Name

Mediwound Ltd

Sector

Healthcare (1082)

Industry

Biotechnology (600)

Phone

Address

Employee

121

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

MDWD's Discussions on Twitter

Compare MDWD vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDWD Mediwound Ltd	14.22	178.77M	14.48M	-26.11M	-23.86M	-2.2591
VRTX Vertex Pharmaceuticals Inc	526.45	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	797.71	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	873.76	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.04	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	358.61	40.62B	5.76B	514.49M	1.10B	4.4813

Mediwound Ltd Stock (MDWD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
May-02-25	Initiated	Alliance Global Partners	Buy
Feb-28-25	Initiated	Craig Hallum	Buy
Jul-16-24	Reiterated	Maxim Group	Buy
Dec-22-22	Initiated	Maxim Group	Buy
Jul-18-22	Resumed	Oppenheimer	Outperform
Sep-23-20	Initiated	BTIG Research	Buy
Nov-28-16	Initiated	Aegis Capital	Buy
Aug-17-16	Initiated	Wells Fargo	Outperform
Apr-16-14	Initiated	Oppenheimer	Outperform

View All

Mediwound Ltd Stock (MDWD) Latest News

07:35 AM

MediWound Q2 2026 Results Highlight EscharEx Trial Progress and New NexoBrid BARDA Agreement - TipRanks

07:35 AM

07:30 AM

MEDIWOUND ($MDWD) Releases Q2 2026 Earnings - Quiver Quantitative

07:30 AM

07:11 AM

MediWound: Q2 Earnings Snapshot - Yahoo Finance

07:11 AM

07:06 AM

MediWound (NASDAQ: MDWD) revenue drops in H1 2026 but guidance held - Stock Titan

07:06 AM

07:00 AM

MediWound's Phase III Wound Trial Targets 216 Patients at About 40 Sites - Stock Titan

07:00 AM

Aug 11, 2026

Technical Reactions to MDWD Trends in Macro Strategies - Stock Traders Daily

Aug 11, 2026